The selective inhibitor of the multifunctional calcium/calmodulin-dependent kinases (CaMK), , arrests a variety of cell types in G 1 . However, the biochemical nature of this G 1 arrest point and the physiological target of KN-93 in G 1 remain controversial. Here we show that in WI-38 human diploid fibroblasts KN-93 reversibly arrested cells in late G 1 prior to detectable cyclin-dependent kinase 4 (cdk4) activation.
Summary
The selective inhibitor of the multifunctional calcium/calmodulin-dependent kinases (CaMK), KN-93, arrests a variety of cell types in G 1 accompanied by elevation of p13 precipitable H1 kinase activity, implying the arrest was downstream of cdk2 activation (2) . Additionally, KN-93 arrests both asynchronous and mitogen stimulated NIH 3T3 cells in G 1 (3, 4) . In contrast to the HeLa cell experiments, this G 1 arrest was characterized by a reduction in both cdk4 and cdk2 activity (3) . These results raise the question as to why KN-93 induces distinct biochemical arrests points in different cell types. One possibility is that the multifunctional CaMKs act at multiple distinct points in G 1 , both upstream and downstream of cdk activation. Another possibility is that the degree of cell immortalization or transformation affects the nature of the KN-93 arrest point. Indeed, in several cell types, transformation reduces the requirements of Ca 2+ and CaM for cell proliferation (5) (6) (7) . Therefore, transformation may also reduce the requirement for CaMK function at certain cell cycle transitions.
Here, we used normal diploid fibroblasts, which are unlikely to have disruptions For experiments, cells were plated at approximately 5000 cells/cm 2 and grown overnight at 37°C and 5% CO 2 . To arrest cells with low serum, they were washed two times with Puck's solution followed by the addition of media containing 0.2% FBS for 26-32 hr.
All cell culture media and supplements were purchased from Gibco-BRL. FBS was obtained from Sigma, Gibco-BRL, or Hyclone, and each time a new lot of serum was used cells were tested to ensure similar growth parameters. KN-93, KN-92, and W-13
were obtained from RBI/Sigma or Seikagaiku.
Flow cytometry and BrdU incorporation
For flow cytometry, 0.5-1.0 x 10 6 cells were trypsinized, pelleted by centrifugation, and resuspended in 200 µl PBS and 800 µl ethanol. Cells were fixed overnight at -20°C and resuspended in 0.5-1.0 ml DNA Prep (Beckman/Coulter).
Samples were analyzed using an EPICS Profile II and EXPO software analysis program (Beckman/Coulter).
To assay BrdU incorporation by immunofluorescence, cells were plated onto Cdk4 kinase assays were carried out based on protocols described by DeGregori, 
Western Analyses and Immunoprecipitation
Following lysis in Cdk4 IP buffer, samples were assayed for protein concentration and 50-100 µg of protein (depending on assay) were separated by SDS-PAGE electrophoresis. For most western blots, proteins were separated by 10-12% SDS-PAGE, but for retinoblastoma protein (pRb) analysis, 6% SDS-PAGE was used in order to ensure separation of the phosphorylated forms. Following gel electrophoresis, proteins were transferred to Immobilin P (Millipore) based on the manufacturer's recommendations for the electrophoretic transfer apparatus (Bio-Rad). 
Gel Filtration Chromatography
To analyze cdk4 and its associated proteins based on molecular weight (Mr), WI-38 extracts were separated by gel filtration chromatography as described previously (11, 12 was injected into the column at a flow rate of 0.4 ml/min. Fractions (0.5 ml) were collected and then used for western analyses (1/10 fraction) and cdk4 IP kinase assays (0.4 ml). The amount of total cdk4 activity recovered from fractions 6-20 was about 40% of the input.
Adenoviral Infection of Cells
All adenoviruses were generated using the AdEasy system first described by CaMKIIα in pRSV was digested with XhoI and XbaI and ligated into pAdTrack-CMV.
Adenovirus constructs encoding cyclin D1 and cdk4 were generous gifts of Marco Crescenzi (13) .
Results

Reversible Inhibition of Late G 1 Progression by KN-93
Ca 2+ /CaM is required in both early and late G 1 and pharmacological inhibition of CaMK function arrests mammalian cells in G 1 (1) . We have previously demonstrated calcineurin to be required in early G 1 to ensure the proper cyclin D1 accumulation in normal diploid fibroblasts, and hypothesized that one or more CaMKs may regulate late 
Inhibition of G 1 Cdk Activity by KN-93
Since KN-93 has been reported to affect the activity of the cdks in G 1 (2,3), we evaluated the activation status of two G 1 cdks, cdk2 and cdk4, in WI-38 cells arrested in and cyclin A/cdk2 to the total cdk2 activity. Since cdk4 activity is required prior to cdk2 activity during normal G 1 progression, we analyzed cdk4 activity by immunoprecipitating cdk4 kinase complexes followed by kinase assays using GST-Rb as an in vitro substrate.
Although control cells demonstrated cdk4 activity at 18 hr. after serum addition, cells treated with KN-93 had profoundly reduced activity at the same time point ( Figure 2B ).
As an in vivo monitor of cdk4 activity, we analyzed the phosphorylation status of endogenous pRb protein by western analysis ( Figure 2C ). In contrast to serum starved cells which exhibit a single immunoreactive band for hypophosphorylated pRb, serum stimulated cells demonstrated a shifted, hyperphosphorylated pRb and an increase in total pRb. KN-93 treated cells contained both forms of pRb, but at extremely reduced levels.
The presence of some hyperphosphorylated pRb probably reflects the low, but detectable, amount of cdk4 activity that exists in the presence of KN-93.
Since Morris and colleagues (3) found that KN-93 prevented cyclin D1 accumulation, and thus prevented cdk4 activation in NIH-3T3 cells, we examined the expression of cyclin D1. In contrast to results in NIH-3T3 cells, KN-93 did not affect the accumulation of cyclin D1 or cdk4 in WI-38 cells ( Figure 2D ). On the other hand, we found that both KN-93 and W-13, a CaM antagonist, had similar effects on G 1 cdk activities and pRb phosphorylation, and our results using W-13 were similar to previously published results for WI-38 cells (14, 15) . In summary, KN-93 arrested WI-38 cells in late G 1 with dramatically reduced cdk4 activity and this G 1 arrest was distinct from the arrest previously reported in NIH-3T3 cells since cyclin D1 levels were unchanged.
Alteration of Cdk4 Complex Formation in the Presence of KN-93
Since cdk4 activity is regulated by cyclin binding, cyclin-dependent kinase inhibitor (CKI) binding, subcellular localization, and phosphorylation status, we evaluated each of these components in KN-93 treated cells (16) (17) (18) (19) (20) . First, cdk4 activity requires complex formation with the D type cyclins and in WI-38 cells, the most abundant complex was found to be cyclin D1/cdk4 (21) . Using antibodies to immunoprecipitate cdk4 complexes, we found similar amounts of both cyclin D1 and (16, 18, 19) . Because the amount of cyclin D1-bound cdk4 is similar in KN-93 treated or untreated cells, we reasoned it was unlikely that cdk4 was inactive due to inhibition by INK4 binding. In contrast to the INK4 proteins, p21/p27 proteins are required for proper assembly and nuclear entry of cdk4 complexes (16, 18, 19) . We analyzed cdk4
immunoprecipitates for p21 and p27, and found similar levels of both proteins in KN-93 treated and untreated cells ( Figure 3B ). Following its assembly with cyclin D, cdk4 requires phosphorylation of Thr172 by the nuclear enzyme, CAK, for full activation. As a phospho-specific antibody to this site on cdk4 is not available, we evaluated Thr phosphorylation of cdk4 by immunoprecipitating cdk4 and probing with an antibody against a phospho-Thr-Pro epitope, as Thr172 is followed by Pro in cdk4. This was possible because mutational analysis showed that Thr172 is the only Thr residue phosphorylated in cdk4 (22) . In cdk4 immunoprecipitates from WI-38 cells, the antibody recognized a single band that comigrated with cdk4 ( Figure 3C ). KN-93 treated cell lysates had immunoreactivity similar to untreated cell lysates. We used cyclosporin Atreated cell extracts, which show no immunoreactivity, as a control sample in which we knew that cdk4 was not bound to cyclin D, and therefore presumed cdk4 would be unphosphorylated. In conclusion, KN-93 neither prevented the assembly of cdk4 complexes containing cyclin D1 or p21/p27 nor the subsequent activating phosphorylation by CAK.
Although CAK is a nuclear enzyme, immunofluorescence microscopy was used to confirm that cyclin D1/cdk4 was localized in the nucleus of KN-93 treated cells. In Since we ruled out the major known regulators of cdk4 activation as targets for the KN-93 arrest, we evaluated cdk4 complexes using gel filtration chromatography (11, 12) . In general, cdk4 has been suggested to partition between 3 major complexes: a large (~450 kDa) chaperone complex with hsp90 and cdc37; an intermediate size (~150 kDa) active complex with cyclin D and p21; and, a small (~50 kDa) inactive complex with an INK4 protein (19) . Importantly, the cdk4 immunoprecipitates from whole cell lysates actually contain a complex mixture of all these diverse cdk4 complexes, and it has been shown that only a small fraction of the total cdk4 exhibits kinase activity. To evaluate the relative amounts of these cdk4 complexes in cells, we fractionated WI-38 cell lysates by gel filtration chromatography followed by western analysis of cdk4 and its binding partners. Whereas, the overall distribution of cdk4 in the fractions was similar in the presence or absence of KN-93, we did identify differences in the migration patterns of cyclin D1 ( Figure 4A ). At 12 hr. after serum addition, in late G 1 , cyclin D1 was present primarily in fractions around 150 kDa, which was expected based on previous data that active cdk4/cyclin D1/p21 complexes were found in this region. However, at 16 hr., cyclin D1 had shifted into lower Mr fractions that span the region from 150 kDa to 60 kDa. In the presence of KN-93 for 16 hr., the distribution of cyclin D1 was strikingly similar to that found at 12 hr. in the absence of the inhibitor, with cyclin D1 limited to fractions around 150 kDa.
Since we detected a change in cyclin D1 fractionation patterns in extracts from cells at 12 and 16 hr., we next examined the activity profiles from those extracts. At 12
hr., the majority of cdk4 activity was present in fractions around 200 kDa with a small additional "peak" of activity around 60 kDa ( Figures 4B and 4C) . By 16 hr., the activity of the 60 kDa complex increased substantially, although activity remained in the region of 200 kDa ( Figures 4B and 4C ). For KN-93 treated cells at 16 hr. after serum addition, the small amount of cdk4 activity was limited to higher Mr fractions around 200 kDa and no activity was found in the region of 60 kDa. Therefore, we suggest that the shift in cyclin D1 to lower Mr fractions around 16 hr. after serum addition corresponds to a shift in cdk4 activity towards that same region.
As WI-38 cells progressed through late G 1 and into S phase, from 12 to 18 hr.
after serum addition, the total cdk4 activity increased several fold ( Figure 4D ). While serum starved cells had no activity (T=0), cells treated with KN-93 routinely had only 10% of the cdk4 activity compared with untreated cells. Thus, we found two important changes in cdk4 activity which occur in late G 1 in normal diploid fibroblasts, although these changes may or may not be related to each other. First, as expected, the total amount of cdk4 activity increases considerably ( Figure 4D ). Second, two major "peaks" of cdk4 activity, one ~200 kDa and one ~60 kDa, appear between 12 and 16 hr. after serum addition, and the change in cdk4 activity corresponds to the change in the cyclin D1 profile (Figures 4A and 4B ). Our results reveal that KN-93 not only reduced the total amount of cdk4 activity by 10 fold, but it also prevented the appearance of cdk4 activity in the ~60 kDa fraction.
Bypass of KN-93 Arrest by cyclin D1/cdk4 Overexpression
To confirm that cyclin D/cdk4 complexes were the critical downstream targets of KN-93 in G 1 , we attempted to bypass the KN-93 arrest with recombinant adenoviruses expressing cyclin D1 and cdk4. Whereas expression of cyclin E/cdk2 in quiescent cells has previously been shown to drive S phase entry, overexpression of cyclin D/cdk4 in quiescent cells neither generated cdk4 activity nor promoted cell cycle progression (24) .
Only after serum addition did overexpressed cyclin D/cdk4 accelerate G 1 progression, suggesting that one or more mitogen-dependent factors were required for cdk4 activity and/or nuclear entry of the cyclin D/cdk4 complex. In untreated WI-38 cells, cyclin D1 or cdk4 expression alone had no effect on reentry but coexpression of cyclin D1 and cdk4
dramatically increased the number of cells in the S and G 2 /M phases ( Figure 5A ). 
Regulation of Cdk4 Activation by CaMKI
Although other investigators have assumed that any cellular effects of KN-93 are due to inhibition of CaMKII, KN-93 inhibits the other multifunctional CaMKs, CaMKI and CaMKIV, at similar concentrations (25, 26) . Therefore, we evaluated the role of all three multifunctional CaMKs in G 1 progression in normal diploid fibroblasts. First, we addressed which CaMKs were expressed in these cells. The expression of CaMKII isoforms has been previously demonstrated in WI-38 cells (27) , so we analyzed the expression of CaMKI and CaMKIV by western analysis in both the asynchronous and serum starved states. We found CaMKI was expressed about equally in both conditions, but could not detect any CaMKIV expression ( Figure 6A ). Since only CaMKI and
CaMKII are expressed in WI-38 cells, we questioned which of these enzymes represented the target of KN-93 in G 1 .
Using an adenovirus based expression system, we expressed kinase-deficient CaMKI or CaMKII proteins to similar amounts in both asynchronous and serum starved cells ( Figure 6B ) and evaluated if overexpression of either protein could prevent cdk4 activation and pRb hyperphosphorylation, similar to KN-93 ( Figures 2B and 2C ).
Figures 6C and 6D clearly demonstrate that overexpression of kinase-deficient CaMKI prevented both cdk4 activation and pRb hyperphosphorylation, whereas overexpression of kinase-deficient CaMKII had neither effect. Therefore, we conclude that CaMKI, not CaMKII, is the likely target of KN-93 in this system.
Discusssion
Here we report that KN-93 arrests human diploid fibroblasts in late G 1 prior to cyclin D1/cdk4 activation and pRb hyperphosphorylation. Although these are the first studies to address the role of CaMK in G 1 regulation in a non-immortalized, nontransformed cell line, the KN-93 arrest is similar to that caused by the CaM antagonist, W-13, previously reported in WI-38 cells (14, 15 complexes at much smaller Mr, 70-100 kDa, and those complexes may not contain p27 (12, 19) . In our studies, active cdk4 complexes are found in both Mr ranges and we demonstrated a shift in the pattern of active cdk4 complexes as cells progress through G 1 .
Between 12 and 16 hr. after serum addition, we found an increase in cdk4 total activity as well as the appearance of a second peak of cdk4 activity in fractions eluting from the column around 70 kDa. These results demonstrate the presence of two distinct, active cdk4 complexes in WI-38 cells and raise the question as to the function of each complex.
In the presence of KN-93 at 16 hr., the small amount of detectable cdk4 activity is Unfortunately, the exact composition and structure of active cyclin D1/cdk4 remain unclear, and the minimal number of proteins required to form active cyclin D/cdk4 complexes is unknown (19) . In vitro, recombinant cyclin D1 and cdk4, purified from bacteria or Sf9 cells, do not assemble into complexes, but if the proteins are coexpressed in Sf9 cells, active cyclin D/cdk4 complexes can be isolated (22, 24) . In 
